Cervical cancer is the 2nd leading cause of female cancer and cancer related deaths of female in Bangladesh. Persistent infection with oncogenic Human Papilloma Virus (HPV) is necessary for cervical carcinogenesis. Vaginal microbiota plays a functional role in the persistence or regression of HPV infections. Vaginal dysbiosis associated with depletion of normally dominated vaginal Lactobacillus occurs in cervical cancer. They have been confirmed to boost immunity, eliminate pathogens, moderate side effects of antibiotic therapy etc. Researchers agree with the critical role of probiotics in getting rid of mutagens, delaying the onset of tumors, alleviating the side effects of chemotherapy. 100 participants with a diagnosis of Low-grade Squamous Intraepithelial Lesion (LSIL) on their latest PAP smear/ Visual Inspection with Acetic Acid (VIA) test, will be selected according to the eligible criteria and distributed into group A, B to receive common care (N=50) and probiotic therapy (N=50) for 6 months respectively. After enrollment, a complete history will be taken from the participants and a thorough physical examination will be conducted and recorded. Respondents will fill up a questionnaire. Informed written consents will be taken. Following all safety precautions and aseptic techniques, Cervical and vaginal swab for the detection of HPV, analysis of microbiota and level of Lactobacillus will be collected on day 0, 180 and a new PAP smear/VIA test will be done after 6 months. Respective sample identification number will be assigned. The study information will be kept anonymous strictly. HPV will be detected using the GP5+/6+ HPV PCR with a high-risk HPV probe cocktail in an enzyme immunoassay format. Samples will be inoculated on preselected culture media for both aerobic and anaerobic culture system. Microbial load of samples will be measured quantitatively and identified based on conventional and advance biochemical tests.